Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells $10,016,587.82 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Dianthus Therapeutics Price Performance

DNTH opened at $77.86 on Monday. The firm has a fifty day moving average price of $52.53 and a 200 day moving average price of $42.82. The stock has a market cap of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). The company had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DNTH. Truist Financial boosted their price target on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research note on Monday, March 9th. HC Wainwright boosted their target price on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $115.33.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Dianthus Therapeutics in the 4th quarter valued at approximately $43,000. Seven Fleet Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the 4th quarter valued at approximately $604,000. Invesco Ltd. lifted its holdings in Dianthus Therapeutics by 125.9% in the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company’s stock valued at $4,182,000 after acquiring an additional 56,560 shares during the last quarter. XTX Topco Ltd acquired a new position in Dianthus Therapeutics in the fourth quarter valued at approximately $550,000. Finally, Voloridge Investment Management LLC grew its position in Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company’s stock worth $1,627,000 after acquiring an additional 17,612 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 “go” decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters’ option), strengthening the company’s cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering…
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics (NASDAQ:DNTH) Raised to “Strong-Buy” at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.